Published: Guidance, quality standards and advice
Showing 151 to 160 of 302
| Title | Reference number | Published | Last updated |
|---|---|---|---|
| Pancreatic cancer | QS177 | ||
| Oesophago-gastric cancer | QS176 | ||
| Vandetanib for treating medullary thyroid cancer | TA550 | ||
| Padeliporfin for untreated localised prostate cancer | TA546 | ||
| Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | IPG628 | ||
| AlignRT in breast cancer radiotherapy | MIB157 | ||
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | ||
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | ||
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | ||
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA529 |